| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 146 | 2025 | 1129 | 20.600 |
Why?
|
| Lung Neoplasms | 184 | 2025 | 2369 | 20.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 63 | 2024 | 2523 | 5.370 |
Why?
|
| Antibodies, Monoclonal, Humanized | 49 | 2025 | 962 | 4.900 |
Why?
|
| Immunotherapy | 36 | 2024 | 703 | 4.250 |
Why?
|
| Antineoplastic Agents, Immunological | 23 | 2025 | 205 | 4.090 |
Why?
|
| ErbB Receptors | 32 | 2023 | 499 | 3.700 |
Why?
|
| B7-H1 Antigen | 36 | 2025 | 279 | 3.620 |
Why?
|
| Protein Kinase Inhibitors | 21 | 2023 | 589 | 3.310 |
Why?
|
| Antineoplastic Agents | 42 | 2023 | 2337 | 3.250 |
Why?
|
| Small Cell Lung Carcinoma | 15 | 2024 | 112 | 3.080 |
Why?
|
| Antibodies, Monoclonal | 32 | 2024 | 1397 | 3.080 |
Why?
|
| Quinazolines | 10 | 2021 | 214 | 2.880 |
Why?
|
| Mutation | 44 | 2024 | 4184 | 2.820 |
Why?
|
| Neoplasms | 26 | 2024 | 3029 | 2.620 |
Why?
|
| Humans | 256 | 2025 | 90568 | 2.180 |
Why?
|
| Thymus Neoplasms | 11 | 2023 | 43 | 2.040 |
Why?
|
| Thoracic Neoplasms | 7 | 2023 | 66 | 1.730 |
Why?
|
| Platinum | 15 | 2024 | 64 | 1.640 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 321 | 1.580 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 307 | 1.580 |
Why?
|
| Neoplasms, Glandular and Epithelial | 7 | 2022 | 75 | 1.430 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 13 | 2024 | 168 | 1.410 |
Why?
|
| Aged | 87 | 2025 | 19404 | 1.410 |
Why?
|
| Molecular Targeted Therapy | 9 | 2021 | 281 | 1.400 |
Why?
|
| Aged, 80 and over | 46 | 2025 | 6812 | 1.340 |
Why?
|
| Male | 108 | 2025 | 42931 | 1.310 |
Why?
|
| Mesothelioma | 9 | 2024 | 326 | 1.270 |
Why?
|
| Etoposide | 11 | 2024 | 203 | 1.250 |
Why?
|
| Pleural Neoplasms | 9 | 2024 | 204 | 1.250 |
Why?
|
| Female | 106 | 2025 | 46855 | 1.220 |
Why?
|
| Pandemics | 11 | 2021 | 788 | 1.180 |
Why?
|
| Biomarkers, Tumor | 20 | 2024 | 1550 | 1.160 |
Why?
|
| Prognosis | 36 | 2024 | 3810 | 1.150 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2024 | 610 | 1.150 |
Why?
|
| Middle Aged | 79 | 2025 | 26327 | 1.140 |
Why?
|
| Neoadjuvant Therapy | 4 | 2024 | 386 | 1.130 |
Why?
|
| Italy | 18 | 2024 | 108 | 1.080 |
Why?
|
| Carboplatin | 12 | 2024 | 311 | 1.080 |
Why?
|
| Programmed Cell Death 1 Receptor | 8 | 2021 | 174 | 1.050 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 202 | 1.020 |
Why?
|
| Registries | 7 | 2025 | 812 | 1.000 |
Why?
|
| Pemetrexed | 8 | 2023 | 76 | 0.950 |
Why?
|
| Taxoids | 6 | 2020 | 124 | 0.950 |
Why?
|
| Camptothecin | 3 | 2024 | 197 | 0.940 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2022 | 1096 | 0.940 |
Why?
|
| Neoplasm Staging | 22 | 2024 | 2018 | 0.930 |
Why?
|
| Colorectal Neoplasms | 12 | 2021 | 974 | 0.930 |
Why?
|
| Mutagenesis, Insertional | 2 | 2021 | 114 | 0.900 |
Why?
|
| Betacoronavirus | 7 | 2020 | 264 | 0.870 |
Why?
|
| Adult | 61 | 2025 | 26940 | 0.870 |
Why?
|
| Survival Rate | 24 | 2024 | 1899 | 0.870 |
Why?
|
| Receptor, ErbB-2 | 4 | 2021 | 253 | 0.860 |
Why?
|
| Medical Oncology | 8 | 2023 | 381 | 0.810 |
Why?
|
| Quality of Life | 13 | 2024 | 1688 | 0.780 |
Why?
|
| Carcinoma, Large Cell | 3 | 2016 | 39 | 0.770 |
Why?
|
| Cisplatin | 10 | 2024 | 599 | 0.760 |
Why?
|
| Disease Progression | 16 | 2023 | 1485 | 0.750 |
Why?
|
| Thymoma | 5 | 2023 | 30 | 0.750 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2021 | 306 | 0.730 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2021 | 665 | 0.730 |
Why?
|
| Macrophages | 3 | 2019 | 585 | 0.730 |
Why?
|
| Piperazines | 4 | 2021 | 284 | 0.700 |
Why?
|
| Coronavirus | 1 | 2020 | 18 | 0.680 |
Why?
|
| Paclitaxel | 4 | 2024 | 484 | 0.680 |
Why?
|
| Follow-Up Studies | 18 | 2024 | 3692 | 0.670 |
Why?
|
| Treatment Outcome | 33 | 2024 | 8373 | 0.670 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 6 | 2023 | 159 | 0.670 |
Why?
|
| Pyrimidines | 8 | 2023 | 371 | 0.660 |
Why?
|
| Retrospective Studies | 37 | 2024 | 9323 | 0.650 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2018 | 19 | 0.620 |
Why?
|
| Receptors, Fc | 1 | 2018 | 32 | 0.620 |
Why?
|
| ras Proteins | 4 | 2015 | 131 | 0.610 |
Why?
|
| Survival Analysis | 15 | 2021 | 1499 | 0.580 |
Why?
|
| Neuroendocrine Tumors | 2 | 2016 | 124 | 0.570 |
Why?
|
| Cholesterol | 1 | 2019 | 362 | 0.560 |
Why?
|
| Genes, ras | 4 | 2012 | 97 | 0.560 |
Why?
|
| Palliative Care | 4 | 2019 | 264 | 0.560 |
Why?
|
| Adenocarcinoma | 8 | 2022 | 1182 | 0.540 |
Why?
|
| Bronchial Neoplasms | 1 | 2016 | 9 | 0.540 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2016 | 34 | 0.540 |
Why?
|
| Receptors, Somatostatin | 1 | 2016 | 34 | 0.530 |
Why?
|
| Carcinoid Tumor | 2 | 2016 | 45 | 0.530 |
Why?
|
| Receptors, Peptide | 1 | 2016 | 25 | 0.530 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 3 | 2024 | 16 | 0.520 |
Why?
|
| Pneumonectomy | 4 | 2024 | 214 | 0.520 |
Why?
|
| Erlotinib Hydrochloride | 7 | 2022 | 88 | 0.520 |
Why?
|
| Genes, erbB-1 | 2 | 2015 | 16 | 0.520 |
Why?
|
| Exons | 6 | 2023 | 453 | 0.510 |
Why?
|
| Disease-Free Survival | 12 | 2020 | 1170 | 0.500 |
Why?
|
| DNA Mutational Analysis | 4 | 2016 | 531 | 0.500 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2021 | 295 | 0.500 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 198 | 0.480 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 50 | 0.480 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 438 | 0.470 |
Why?
|
| Metformin | 3 | 2024 | 131 | 0.470 |
Why?
|
| Radiotherapy | 3 | 2021 | 318 | 0.460 |
Why?
|
| Brain Neoplasms | 4 | 2022 | 781 | 0.460 |
Why?
|
| Oncologists | 4 | 2021 | 39 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2024 | 846 | 0.450 |
Why?
|
| Biomarkers | 8 | 2023 | 1797 | 0.440 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2023 | 147 | 0.440 |
Why?
|
| CTLA-4 Antigen | 4 | 2024 | 140 | 0.430 |
Why?
|
| Neuralgia | 1 | 2013 | 31 | 0.420 |
Why?
|
| Quinazolinones | 1 | 2013 | 15 | 0.420 |
Why?
|
| Eye Diseases | 1 | 2013 | 59 | 0.420 |
Why?
|
| Oxycodone | 1 | 2013 | 35 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1286 | 0.410 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 85 | 0.410 |
Why?
|
| Chemoradiotherapy | 5 | 2022 | 304 | 0.410 |
Why?
|
| Double-Blind Method | 6 | 2024 | 1726 | 0.390 |
Why?
|
| Biological Products | 1 | 2014 | 166 | 0.390 |
Why?
|
| Piperidines | 3 | 2022 | 163 | 0.380 |
Why?
|
| Pyridazines | 2 | 2022 | 21 | 0.370 |
Why?
|
| Immunohistochemistry | 11 | 2021 | 1806 | 0.370 |
Why?
|
| Decision Support Techniques | 2 | 2024 | 170 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 1357 | 0.360 |
Why?
|
| Bevacizumab | 6 | 2022 | 268 | 0.360 |
Why?
|
| Sequence Deletion | 1 | 2011 | 205 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 806 | 0.360 |
Why?
|
| Nuclear Proteins | 4 | 2023 | 728 | 0.350 |
Why?
|
| Liver Neoplasms | 4 | 2020 | 760 | 0.350 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2024 | 477 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2020 | 200 | 0.350 |
Why?
|
| Platinum Compounds | 3 | 2019 | 28 | 0.350 |
Why?
|
| Endonucleases | 3 | 2021 | 23 | 0.340 |
Why?
|
| Tumor Burden | 3 | 2023 | 316 | 0.340 |
Why?
|
| Fasting | 2 | 2021 | 166 | 0.340 |
Why?
|
| Acrylamides | 3 | 2018 | 34 | 0.330 |
Why?
|
| Interferons | 1 | 2010 | 127 | 0.330 |
Why?
|
| Prospective Studies | 8 | 2023 | 4345 | 0.330 |
Why?
|
| Signal Transduction | 3 | 2021 | 3426 | 0.330 |
Why?
|
| Pneumonia | 2 | 2023 | 184 | 0.330 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 133 | 0.320 |
Why?
|
| Aniline Compounds | 3 | 2018 | 59 | 0.320 |
Why?
|
| Neoplasm Metastasis | 9 | 2024 | 1066 | 0.320 |
Why?
|
| Referral and Consultation | 2 | 2024 | 349 | 0.320 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2021 | 854 | 0.320 |
Why?
|
| Cohort Studies | 6 | 2022 | 2893 | 0.320 |
Why?
|
| Radiosurgery | 2 | 2024 | 286 | 0.320 |
Why?
|
| Combined Modality Therapy | 6 | 2024 | 1708 | 0.310 |
Why?
|
| Smoking | 2 | 2016 | 627 | 0.310 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1247 | 0.300 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 2607 | 0.290 |
Why?
|
| Time Factors | 8 | 2021 | 5365 | 0.280 |
Why?
|
| Immunoconjugates | 2 | 2024 | 115 | 0.270 |
Why?
|
| Perioperative Care | 2 | 2024 | 171 | 0.270 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2023 | 493 | 0.260 |
Why?
|
| Cetuximab | 8 | 2012 | 116 | 0.260 |
Why?
|
| Models, Statistical | 1 | 2009 | 575 | 0.250 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2024 | 290 | 0.250 |
Why?
|
| Steroids | 3 | 2022 | 173 | 0.250 |
Why?
|
| Precision Medicine | 2 | 2024 | 413 | 0.250 |
Why?
|
| Stomach Neoplasms | 1 | 2008 | 288 | 0.240 |
Why?
|
| Bone Neoplasms | 2 | 2023 | 321 | 0.240 |
Why?
|
| Diarrhea | 2 | 2018 | 178 | 0.240 |
Why?
|
| Pyrazoles | 2 | 2018 | 151 | 0.240 |
Why?
|
| Transcription Factors | 4 | 2023 | 1673 | 0.240 |
Why?
|
| Europe | 6 | 2021 | 328 | 0.240 |
Why?
|
| Young Adult | 11 | 2021 | 6425 | 0.230 |
Why?
|
| Lung | 6 | 2023 | 1305 | 0.230 |
Why?
|
| Gene Dosage | 2 | 2016 | 210 | 0.230 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 3 | 2019 | 59 | 0.230 |
Why?
|
| Global Burden of Disease | 2 | 2020 | 10 | 0.220 |
Why?
|
| Salvage Therapy | 3 | 2021 | 233 | 0.220 |
Why?
|
| DNA Repair | 2 | 2016 | 363 | 0.220 |
Why?
|
| Pleura | 2 | 2024 | 32 | 0.220 |
Why?
|
| Telemedicine | 3 | 2021 | 196 | 0.220 |
Why?
|
| Animals | 14 | 2024 | 27691 | 0.220 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2021 | 276 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 48 | 0.200 |
Why?
|
| Thymectomy | 1 | 2022 | 31 | 0.200 |
Why?
|
| Colonic Neoplasms | 2 | 2006 | 571 | 0.200 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2016 | 354 | 0.200 |
Why?
|
| Autoimmune Diseases | 2 | 2022 | 252 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 491 | 0.200 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1882 | 0.200 |
Why?
|
| Cytokines | 3 | 2021 | 813 | 0.200 |
Why?
|
| Societies, Medical | 3 | 2021 | 591 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2024 | 320 | 0.200 |
Why?
|
| Mice, Nude | 3 | 2018 | 819 | 0.190 |
Why?
|
| Myasthenia Gravis | 1 | 2022 | 83 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 42 | 0.190 |
Why?
|
| Disease Management | 3 | 2021 | 332 | 0.190 |
Why?
|
| Inflammation Mediators | 1 | 2022 | 155 | 0.190 |
Why?
|
| Fatty Acids | 1 | 2022 | 141 | 0.190 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 283 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2023 | 193 | 0.190 |
Why?
|
| Compassionate Use Trials | 1 | 2021 | 6 | 0.190 |
Why?
|
| Risk Factors | 7 | 2021 | 5580 | 0.190 |
Why?
|
| Research | 1 | 2022 | 252 | 0.180 |
Why?
|
| Tubulin Modulators | 1 | 2021 | 23 | 0.180 |
Why?
|
| Immunologic Factors | 2 | 2019 | 172 | 0.180 |
Why?
|
| Immunosenescence | 1 | 2020 | 4 | 0.180 |
Why?
|
| Myeloid Cells | 1 | 2021 | 103 | 0.180 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 31 | 0.180 |
Why?
|
| Pyridines | 3 | 2021 | 303 | 0.180 |
Why?
|
| Deoxycytidine | 1 | 2021 | 212 | 0.180 |
Why?
|
| Clinical Trials as Topic | 8 | 2024 | 1141 | 0.170 |
Why?
|
| Adolescent | 7 | 2023 | 9353 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2020 | 30 | 0.170 |
Why?
|
| Information Dissemination | 1 | 2021 | 116 | 0.170 |
Why?
|
| Leadership | 1 | 2021 | 143 | 0.170 |
Why?
|
| Radiation Oncology | 1 | 2021 | 122 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2019 | 37 | 0.160 |
Why?
|
| International Cooperation | 4 | 2020 | 126 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1054 | 0.160 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2019 | 30 | 0.160 |
Why?
|
| Cause of Death | 1 | 2020 | 270 | 0.160 |
Why?
|
| Circulating MicroRNA | 1 | 2019 | 13 | 0.160 |
Why?
|
| Social Media | 1 | 2021 | 98 | 0.160 |
Why?
|
| Nausea | 2 | 2013 | 176 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 124 | 0.160 |
Why?
|
| Vaccination | 1 | 2021 | 280 | 0.160 |
Why?
|
| Vomiting | 2 | 2013 | 196 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 240 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 1735 | 0.160 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 22 | 0.150 |
Why?
|
| MicroRNAs | 2 | 2021 | 561 | 0.150 |
Why?
|
| Injection Site Reaction | 1 | 2018 | 2 | 0.150 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2018 | 16 | 0.150 |
Why?
|
| 4-Butyrolactone | 1 | 2018 | 3 | 0.150 |
Why?
|
| Drug Approval | 1 | 2019 | 65 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 83 | 0.150 |
Why?
|
| Consensus | 1 | 2020 | 371 | 0.150 |
Why?
|
| Sarcoma | 1 | 2020 | 217 | 0.150 |
Why?
|
| Inflammation | 2 | 2021 | 990 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2019 | 188 | 0.150 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 91 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 75 | 0.150 |
Why?
|
| Mice, SCID | 1 | 2018 | 260 | 0.150 |
Why?
|
| Biomedical Research | 2 | 2021 | 403 | 0.150 |
Why?
|
| Niacinamide | 1 | 2018 | 100 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2021 | 322 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2019 | 174 | 0.140 |
Why?
|
| Mobile Applications | 1 | 2019 | 72 | 0.140 |
Why?
|
| Organoplatinum Compounds | 4 | 2016 | 94 | 0.140 |
Why?
|
| Pulmonary Medicine | 1 | 2018 | 47 | 0.140 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 95 | 0.140 |
Why?
|
| Sodium | 1 | 2018 | 334 | 0.140 |
Why?
|
| Hospitalization | 2 | 2020 | 899 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 265 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 229 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 3 | 2024 | 167 | 0.140 |
Why?
|
| NF-kappa B | 1 | 2020 | 469 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2024 | 168 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 274 | 0.140 |
Why?
|
| Fatigue | 1 | 2018 | 176 | 0.140 |
Why?
|
| Thrombosis | 1 | 2020 | 312 | 0.140 |
Why?
|
| Patient Selection | 4 | 2021 | 682 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 274 | 0.140 |
Why?
|
| Research Design | 2 | 2018 | 590 | 0.140 |
Why?
|
| Melanoma | 1 | 2021 | 473 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1085 | 0.130 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 159 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 315 | 0.130 |
Why?
|
| DNA Damage | 1 | 2018 | 374 | 0.130 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 67 | 0.130 |
Why?
|
| Recurrence | 2 | 2017 | 1162 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2024 | 167 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 46 | 0.130 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 478 | 0.130 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 180 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 399 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 157 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 842 | 0.120 |
Why?
|
| Gases | 1 | 2014 | 30 | 0.120 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 3019 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1873 | 0.110 |
Why?
|
| Portal Vein | 1 | 2014 | 122 | 0.110 |
Why?
|
| Breast Neoplasms, Male | 1 | 2013 | 31 | 0.110 |
Why?
|
| Pregabalin | 1 | 2013 | 6 | 0.110 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2014 | 56 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 2667 | 0.100 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2013 | 35 | 0.100 |
Why?
|
| Eye | 1 | 2013 | 111 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1935 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 145 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2012 | 135 | 0.100 |
Why?
|
| Fluorouracil | 3 | 2012 | 548 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 476 | 0.100 |
Why?
|
| Caloric Restriction | 2 | 2024 | 14 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2013 | 291 | 0.100 |
Why?
|
| Polypharmacy | 2 | 2021 | 15 | 0.090 |
Why?
|
| Stents | 1 | 2014 | 415 | 0.090 |
Why?
|
| Mastectomy | 1 | 2013 | 252 | 0.090 |
Why?
|
| Forecasting | 2 | 2009 | 306 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 2 | 2021 | 34 | 0.090 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 52 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 792 | 0.090 |
Why?
|
| Topotecan | 1 | 2010 | 45 | 0.090 |
Why?
|
| Psychotherapy | 1 | 2011 | 73 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 776 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2021 | 2335 | 0.080 |
Why?
|
| Mice | 5 | 2024 | 11932 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 269 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 2702 | 0.080 |
Why?
|
| Jaw Diseases | 1 | 2008 | 8 | 0.080 |
Why?
|
| Health Personnel | 2 | 2021 | 215 | 0.080 |
Why?
|
| Osteonecrosis | 1 | 2008 | 22 | 0.080 |
Why?
|
| Hematinics | 1 | 2008 | 11 | 0.080 |
Why?
|
| Diphosphonates | 1 | 2008 | 33 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 2424 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 866 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2008 | 42 | 0.070 |
Why?
|
| Blepharoptosis | 1 | 2007 | 11 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2008 | 90 | 0.070 |
Why?
|
| Imidazoles | 1 | 2008 | 138 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 2 | 2013 | 82 | 0.070 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2007 | 29 | 0.070 |
Why?
|
| Biopsy | 2 | 2023 | 1192 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2008 | 234 | 0.070 |
Why?
|
| Anemia | 1 | 2008 | 133 | 0.070 |
Why?
|
| Decision Making | 2 | 2024 | 672 | 0.070 |
Why?
|
| Gene Expression | 3 | 2021 | 1312 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2011 | 419 | 0.070 |
Why?
|
| Genotype | 3 | 2015 | 1855 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1741 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 179 | 0.070 |
Why?
|
| Antiemetics | 1 | 2007 | 98 | 0.060 |
Why?
|
| NIH 3T3 Cells | 2 | 2016 | 111 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2017 | 298 | 0.060 |
Why?
|
| Floxuridine | 1 | 2005 | 10 | 0.060 |
Why?
|
| Foot | 1 | 2005 | 53 | 0.060 |
Why?
|
| Dermatitis | 1 | 2005 | 34 | 0.060 |
Why?
|
| United States | 3 | 2023 | 7142 | 0.060 |
Why?
|
| Oximes | 1 | 2024 | 16 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 684 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 88 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 538 | 0.060 |
Why?
|
| Anxiety | 2 | 2021 | 313 | 0.060 |
Why?
|
| Placebos | 1 | 2024 | 211 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2024 | 154 | 0.060 |
Why?
|
| Hand | 1 | 2005 | 143 | 0.060 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 59 | 0.060 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 36 | 0.050 |
Why?
|
| European Union | 1 | 2023 | 8 | 0.050 |
Why?
|
| North America | 1 | 2023 | 188 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 43 | 0.050 |
Why?
|
| Tetraspanins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Tetraspanin 28 | 1 | 2022 | 3 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 84 | 0.050 |
Why?
|
| Armed Conflicts | 1 | 2022 | 2 | 0.050 |
Why?
|
| Ukraine | 1 | 2022 | 20 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 169 | 0.050 |
Why?
|
| Comorbidity | 2 | 2020 | 955 | 0.050 |
Why?
|
| Survivors | 1 | 2023 | 191 | 0.050 |
Why?
|
| Oncogene Addiction | 1 | 2022 | 2 | 0.050 |
Why?
|
| Uncertainty | 1 | 2022 | 75 | 0.050 |
Why?
|
| Patient Participation | 1 | 2024 | 227 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 45 | 0.050 |
Why?
|
| Norway | 1 | 2021 | 10 | 0.050 |
Why?
|
| Authorship | 1 | 2021 | 23 | 0.050 |
Why?
|
| Spain | 1 | 2021 | 33 | 0.050 |
Why?
|
| Biology | 1 | 2021 | 52 | 0.050 |
Why?
|
| Oncology Nursing | 1 | 2021 | 9 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 453 | 0.050 |
Why?
|
| Netherlands | 1 | 2021 | 24 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 888 | 0.050 |
Why?
|
| Carbazoles | 1 | 2021 | 33 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2022 | 275 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2021 | 54 | 0.050 |
Why?
|
| Epidemics | 1 | 2021 | 31 | 0.050 |
Why?
|
| Computational Biology | 1 | 2024 | 552 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 196 | 0.050 |
Why?
|
| Antigen-Antibody Complex | 1 | 2021 | 87 | 0.050 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 36 | 0.050 |
Why?
|
| Neutrophils | 1 | 2022 | 313 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2021 | 244 | 0.040 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2020 | 9 | 0.040 |
Why?
|
| United Kingdom | 1 | 2021 | 167 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 1594 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 10 | 0.040 |
Why?
|
| Fear | 1 | 2021 | 80 | 0.040 |
Why?
|
| China | 1 | 2021 | 238 | 0.040 |
Why?
|
| Child | 2 | 2022 | 7216 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 98 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2022 | 470 | 0.040 |
Why?
|
| Edema | 1 | 2020 | 71 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 200 | 0.040 |
Why?
|
| Leucovorin | 2 | 2012 | 222 | 0.040 |
Why?
|
| Health Surveys | 1 | 2021 | 239 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 167 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2024 | 1583 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 148 | 0.040 |
Why?
|
| Patient Preference | 1 | 2021 | 117 | 0.040 |
Why?
|
| Immunity | 1 | 2020 | 141 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 140 | 0.040 |
Why?
|
| Sex Factors | 1 | 2023 | 1074 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 338 | 0.040 |
Why?
|
| Administration, Metronomic | 1 | 2019 | 2 | 0.040 |
Why?
|
| Global Health | 1 | 2021 | 192 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 107 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 130 | 0.040 |
Why?
|
| Phenotype | 2 | 2016 | 2471 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 285 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 34 | 0.040 |
Why?
|
| Adenosine | 1 | 2022 | 242 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2018 | 20 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 177 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 103 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2019 | 34 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 312 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 320 | 0.040 |
Why?
|
| Cell Growth Processes | 1 | 2018 | 85 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2018 | 29 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 55 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 625 | 0.040 |
Why?
|
| Paris | 1 | 2018 | 5 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 39 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 1259 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1228 | 0.040 |
Why?
|
| Azacitidine | 1 | 2019 | 148 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 307 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2017 | 21 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1751 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2018 | 38 | 0.040 |
Why?
|
| Oncogenes | 1 | 2018 | 97 | 0.040 |
Why?
|
| Standard of Care | 1 | 2018 | 65 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2018 | 344 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 117 | 0.040 |
Why?
|
| Social Networking | 1 | 2018 | 76 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2022 | 984 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 260 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2017 | 129 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 218 | 0.030 |
Why?
|
| Transfection | 1 | 2018 | 910 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2016 | 52 | 0.030 |
Why?
|
| Proteomics | 1 | 2018 | 241 | 0.030 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 42 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 419 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 601 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 474 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 84 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1919 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 64 | 0.030 |
Why?
|
| Asbestos | 1 | 2015 | 22 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2015 | 38 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2015 | 51 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 354 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 123 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2015 | 52 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 96 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2016 | 173 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 111 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 219 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2015 | 67 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1688 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2501 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 103 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2782 | 0.030 |
Why?
|
| Colonic Diseases | 1 | 2014 | 61 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 441 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 794 | 0.030 |
Why?
|
| Intestinal Obstruction | 1 | 2014 | 89 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2015 | 511 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 3064 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 791 | 0.030 |
Why?
|
| Contrast Media | 1 | 2018 | 1085 | 0.030 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2013 | 12 | 0.030 |
Why?
|
| SEER Program | 1 | 2014 | 201 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 431 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 472 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 987 | 0.030 |
Why?
|
| Carcinosarcoma | 1 | 2013 | 23 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 120 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 827 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 266 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1460 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2014 | 680 | 0.030 |
Why?
|
| Germany | 1 | 2012 | 74 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 176 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 875 | 0.030 |
Why?
|
| Radiography | 1 | 2014 | 809 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 1138 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2022 | 2342 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1723 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 395 | 0.020 |
Why?
|
| Glutamates | 1 | 2011 | 88 | 0.020 |
Why?
|
| Adjustment Disorders | 1 | 2011 | 6 | 0.020 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2013 | 176 | 0.020 |
Why?
|
| Causality | 1 | 2011 | 80 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2892 | 0.020 |
Why?
|
| Guanine | 1 | 2011 | 207 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 294 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 455 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 125 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2011 | 152 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2011 | 222 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2011 | 159 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2010 | 477 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1547 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2011 | 116 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 219 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 982 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1607 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2008 | 5 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 238 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 440 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2008 | 195 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2364 | 0.020 |
Why?
|
| Depression | 1 | 2011 | 518 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 878 | 0.020 |
Why?
|
| X-Ray Film | 1 | 2005 | 36 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2005 | 36 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2030 | 0.010 |
Why?
|
| Syndrome | 1 | 2005 | 452 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 539 | 0.010 |
Why?
|
| Catheterization | 1 | 2005 | 239 | 0.010 |
Why?
|